New hope for CAH: drug may slash steroid use

NCT ID NCT04490915

Ongoing Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called crinecerfont in adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that requires lifelong steroid treatment. The goal is to see if crinecerfont can safely reduce the daily steroid dose needed while keeping hormone levels under control. About 182 participants will receive either crinecerfont or a placebo for 24 weeks, followed by open-label treatment for up to 3 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSIC CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-HYDROXYLASE DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency congenital adrenal hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL ADRENAL HYPERPLASIA

Contacts and locations

Locations

Neurocrine Clinical Site

Los Angeles, California, 90027, United States
Neurocrine Clinical Site

San Diego, California, 92123, United States
Neurocrine Clinical Site

San Francisco, California, 94143, United States
Neurocrine Clinical Site

Aurora, Colorado, 80045, United States
Neurocrine Clinical Site

Atlanta, Georgia, 30329, United States
Neurocrine Clinical Site

Indianapolis, Indiana, 46202, United States
Neurocrine Clinical Site

Bethesda, Maryland, 20982, United States
Neurocrine Clinical Site

Boston, Massachusetts, 02115, United States
Neurocrine Clinical Site

Ann Arbor, Michigan, 48109, United States
Neurocrine Clinical Site

Minneapolis, Minnesota, 55454, United States
Neurocrine Clinical Site

Rochester, Minnesota, 55905, United States
Neurocrine Clinical Site

St Louis, Missouri, 63110, United States
Neurocrine Clinical Site

Great Neck, New York, 11021, United States
Neurocrine Clinical Site

New York, New York, 10029, United States
Neurocrine Clinical Site

Winston-Salem, North Carolina, 27157, United States
Neurocrine Clinical Site

Tulsa, Oklahoma, 74135, United States
Neurocrine Clinical Site

Philadelphia, Pennsylvania, 19104, United States
Neurocrine Clinical Site

Pittsburgh, Pennsylvania, 15224, United States
Neurocrine Clinical Site

Dallas, Texas, 75390, United States
Neurocrine Clinical Site

Seattle, Washington, 98105, United States
Neurocrine Clinical Site

Graz, 8036, Austria
Neurocrine Clinical Site

Vienna, 1090, Austria
Neurocrine Clinical Site

Brussels, 1070, Belgium
Neurocrine Clinical Site

Leuven, 3000, Belgium
Neurocrine Clinical Site

Sofia, 1431, Bulgaria
Neurocrine Clinical Site

Sofia, 1606, Bulgaria
Neurocrine Clinical Site

Halifax, Nova Scotia, B3H 2Y9, Canada
Neurocrine Clinical Site

Hradec Králové, 50005, Czechia
Neurocrine Clinical Site

Angers, 49933, France
Neurocrine Clinical Site

Grenoble, 38700, France
Neurocrine Clinical Site

Le Kremlin-Bicêtre, 94270, France
Neurocrine Clinical Site

Nantes, 44093, France
Neurocrine Clinical Site

Paris, 75651, France
Neurocrine Clinical Site

Paris, 75679, France
Neurocrine Clinical Site

Dresden, 01307, Germany
Neurocrine Clinical Site

Essen, 45147, Germany
Neurocrine Clinical Site

Frankfurt, 60590, Germany
Neurocrine Clinical Site

Leipzig, 04103, Germany
Neurocrine Clinical Site

Munich, 80336, Germany
Neurocrine Clinical Site

Athens, 106 76, Greece
Neurocrine Clinical Site

Athens, 115 27, Greece
Neurocrine Clinical Site

Athens, 11527, Greece
Neurocrine Clinical Site

Thessaloniki, 54642, Greece
Neurocrine Clinical Site

Afula, 1834111, Israel
Neurocrine Clinical Site

Beersheba, 8410101, Israel
Neurocrine Clinical Site

Petah Tikva, 4941480, Israel
Neurocrine Clinical Site

Tel Aviv, 64239, Israel
Neurocrine Clinical Site

Ancona, 60126, Italy
Neurocrine Clinical Site

Bologna, 40138, Italy
Neurocrine Clinical Site

Florence, 50139, Italy
Neurocrine Clinical Site

Messina, 98125, Italy
Neurocrine Clinical Site

Milan, 20132, Italy
Neurocrine Clinical Site

Milan, 20149, Italy
Neurocrine Clinical Site

Naples, 80131, Italy
Neurocrine Clinical Site

Padova, 35128, Italy
Neurocrine Clinical Site

Roma, 00161, Italy
Neurocrine Clinical Site

Leiden, 2333, Netherlands
Neurocrine Clinical Site

Krakow, 31-011, Poland
Neurocrine Clinical Site

Poznan, 60-355, Poland
Neurocrine Clinical Site

Warsaw, 01-809, Poland
Neurocrine Clinical Site

Porto, 4200-319, Portugal
Neurocrine Clinical Site

Belgrade, 11000, Serbia
Neurocrine Clinical Site

Madrid, 28034, Spain
Neurocrine Clinical Site

Seville, 41013, Spain
Neurocrine Clinical Site

Gothenburg, 41345, Sweden
Neurocrine Clinical Site

Stockholm, 17176, Sweden
Neurocrine Clinical Site

Cardiff, CF14 4HH, United Kingdom
Neurocrine Clinical Site

London, WC1B 5EH, United Kingdom
Neurocrine Clinical Site

Manchester, M20 4BX, United Kingdom
Neurocrine Clinical Site

Salford, M6 8HD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.